Expert Review of Clinical Immunology最新文献_第2页

Type 2 inflammation: a Portuguese consensus using Web-Delphi and decision conferencing (INFLAT2-PT). 2型炎症：使用Web-Delphi和决策会议（INFLAT2-PT）的葡萄牙共识。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-03-01 Epub Date: 2025-01-07 DOI: 10.1080/1744666X.2024.2448990

Suzete Costa, João Pedro Aguiar, Mónica D Oliveira, João Gonçalves, João Carlos Ribeiro, Luís Taborda-Barata, Helena Farinha, Pedro Escada, Samuel Fernandes, Luís Soares-de-Almeida, Maria João Paiva-Lopes, Cláudia Chaves Loureiro, Isabel Lourinho, João A Fonseca, Marta Drummond, Rui Tato Marinho, João Bana E Costa, António Vaz Carneiro, Carlos A Bana E Costa

{"title":"Type 2 inflammation: a Portuguese consensus using Web-Delphi and decision conferencing (INFLAT2-PT).","authors":"Suzete Costa, João Pedro Aguiar, Mónica D Oliveira, João Gonçalves, João Carlos Ribeiro, Luís Taborda-Barata, Helena Farinha, Pedro Escada, Samuel Fernandes, Luís Soares-de-Almeida, Maria João Paiva-Lopes, Cláudia Chaves Loureiro, Isabel Lourinho, João A Fonseca, Marta Drummond, Rui Tato Marinho, João Bana E Costa, António Vaz Carneiro, Carlos A Bana E Costa","doi":"10.1080/1744666X.2024.2448990","DOIUrl":"10.1080/1744666X.2024.2448990","url":null,"abstract":"Objectives: Atopic/allergic diseases impose a growing burden on public health, affecting millions of patients worldwide. The main objective of this study was to develop a national expert consensus on relevant clinical questions related to type 2 inflammation.Methods: We conducted: a comprehensive literature review with a qualitative analysis to identify the most repeated themes on the overlap of conditions; a modified 3-round Web-Delphi (or e-Delphi); and a final online decision conference.Results: We included 51 studies. Following three Web-Delphi rounds, we ended up with 30 statements with a 76% overall full agreement rate, 16% agreement, 2% disagreement, and 0% full disagreement. The decision conference enabled adjustments, and the expert panel agreed unanimously on the final set of statements. The consensus used evidence synthesis, Web-Delphi, and decision conference to produce 30 statements on type 2 inflammation as a driver for multimorbidity in asthma, certain rhinitis phenotypes, atopic dermatitis, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis grouped under five domains in underlying pathophysiology, multimorbidity, diagnosis and management, multidisciplinary management, and impact on mental health.Conclusion: We expect the first Portuguese expert consensus INFLAT2-PT to promote understanding of type 2 inflammation diseases, multidisciplinary care, integrated care pathways, future research, and inform health authorities.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"377-391"},"PeriodicalIF":3.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142921264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in tumor immunotherapy targeting macrophages. 靶向巨噬细胞的肿瘤免疫治疗研究进展。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-03-01 Epub Date: 2024-12-11 DOI: 10.1080/1744666X.2024.2438721

Binrui Shi, Meng Du, Zhiyi Chen

{"title":"Advances in tumor immunotherapy targeting macrophages.","authors":"Binrui Shi, Meng Du, Zhiyi Chen","doi":"10.1080/1744666X.2024.2438721","DOIUrl":"10.1080/1744666X.2024.2438721","url":null,"abstract":"Introduction: In recent years, immunotherapy has shown significant therapeutic potential in patients with advanced tumors. However, only a small number of individuals benefit, mainly due to the tumor microenvironment (TME), which provides conditions for the development of tumors. Macrophages in TME, known as tumor-associated macrophages (TAM), are mainly divided into M1 anti-tumor and M2 pro-tumor phenotypes, which play a regulatory role in various stages of tumorigenesis, promote tumorigenesis and metastasis, and cause immunotherapy resistance.Areas covered: This review focuses on research strategies and preclinical/clinical research progress in translating TAM into antitumor phenotype by referring to the PubMed database for five years. These include small molecule chemotherapy drug development, metabolic regulation, gene editing, physical stimulation, nanotechnology-mediated combination therapy strategies, and chimeric antigen receptor-based immunotherapy.Expert opinion: It is necessary to explore the surface-specific receptors and cell signaling pathways of TAM further to improve the specificity and targeting of drugs and to strengthen research in the field of probes that can monitor changes in TAM in real time. In addition, the physical stimulation polarization strategy has the advantages of being noninvasive, economical, and stable and will have excellent clinical transformation value in the future.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"259-276"},"PeriodicalIF":3.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142785063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The "entanglement" between bullous pemphigoid and diabetes mellitus: a comprehensive review and expert recommendations. 大疱性类天疱疮与糖尿病之间的 "纠葛"：全面回顾与专家建议。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-03-01 Epub Date: 2024-11-13 DOI: 10.1080/1744666X.2024.2428621

Jing-Hui Li, Ya-Gang Zuo

{"title":"The \"entanglement\" between bullous pemphigoid and diabetes mellitus: a comprehensive review and expert recommendations.","authors":"Jing-Hui Li, Ya-Gang Zuo","doi":"10.1080/1744666X.2024.2428621","DOIUrl":"10.1080/1744666X.2024.2428621","url":null,"abstract":"Introduction: Bullous pemphigoid (BP) is an autoimmune bullous disease characterized by subepidermal tense blisters, accompanied by urticarial or eczema-like lesions. Circulating autoantibodies in BP patients target BP180 and BP230 at the dermal-epidermal junction. There has been a growing interest in unraveling the intricate relationship between BP and diabetes mellitus (DM), but a comprehensive review is lacking.Areas covered: A thorough search of PubMed was conducted to identify studies concerning the association between BP and DM (1978-2023). Our findings comprehensively summarize the intricate association between BP and DM, focusing on the characteristics, potential pathomechanisms, and the influence of various antidiabetic medications on BP development.Expert opinion: DM emerges as a prevalent comorbidity and potential risk factor for BP. New-onset DM can manifest during BP treatment, primarily due to corticosteroid therapy. Among all antidiabetic medications, dipeptidyl peptidase-IV inhibitors (DPP-4i) have the most solid association with BP onset. Other antidiabetic medications have also been reportedly associated with BP, including meglitinides, glucagon-like peptide 1 (GLP-1)-receptor agonists, and sodium-dependent glucose transporters 2 inhibitors (SGLT-2i). We suggest prescribing DPP-4i in caution for elderly DM patients with a history of autoimmune diseases.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"333-346"},"PeriodicalIF":3.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hemophagocytic lymphohistiocytosis post chimeric antigen receptor T cell therapies. 嵌合抗原受体后的噬血细胞淋巴组织细胞病T细胞治疗。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-03-01 Epub Date: 2024-12-30 DOI: 10.1080/1744666X.2024.2444673

Jing-Ming Wang, Hui-Wen Jiang, Yin-Qiang Zhang, Yu Hu, Heng Mei

{"title":"Hemophagocytic lymphohistiocytosis post chimeric antigen receptor T cell therapies.","authors":"Jing-Ming Wang, Hui-Wen Jiang, Yin-Qiang Zhang, Yu Hu, Heng Mei","doi":"10.1080/1744666X.2024.2444673","DOIUrl":"10.1080/1744666X.2024.2444673","url":null,"abstract":"Introduction: Besides cytokine release syndromes (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), immune effector cell-associated HLH-like syndrome (IEC-HS) is increasingly recognized across CAR-T recipients. This emergent and fatal syndrome is difficult to separate from other disorders during the early phase, and urgently requires more integrated diagnostic and therapeutic frameworks.Areas covered: Existing literature has pointed out the potential role of unbridled proliferation of cytotoxic T lymphocytes, lymphopenia of natural killing cells, and hypercytokinemia in triggering the IEC-HS. The onset time of IEC-HS usually overlaps with CRS or be delayed from CRS. Clinical features include hyperferritinemia, hepatic and renal dysfunctions, cytopenias, coagulopathy, and hemophagocytosis. Multiple diagnostic criteria are based predominantly on ferritin elevation and prerequisite CRS. Corticosteroids are the cornerstone for IEC-HS treatment, while cytokine-targeted agents and pathway inhibitors offer great promise in alleviating IEC-HS syndromes.Expert opinions: Several controversial predisposing factors of IEC-HS such as disease burden should be further investigated. Future research is anticipated to identify the real-time biomarkers, as well as develop a more sophisticated grading and management network.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"277-289"},"PeriodicalIF":3.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142893266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Infectious complications and the utility of serum and cellular markers of infections in the setting of allogeneic hematopoietic stem cell transplantation. 异体造血干细胞移植的感染并发症及血清和细胞感染标志物的应用。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-03-01 Epub Date: 2025-01-08 DOI: 10.1080/1744666X.2025.2450014

Håkon Reikvam, Galina Tsykunova, Miriam Sandnes, Øystein Wendelbo

{"title":"Infectious complications and the utility of serum and cellular markers of infections in the setting of allogeneic hematopoietic stem cell transplantation.","authors":"Håkon Reikvam, Galina Tsykunova, Miriam Sandnes, Øystein Wendelbo","doi":"10.1080/1744666X.2025.2450014","DOIUrl":"10.1080/1744666X.2025.2450014","url":null,"abstract":"Introduction: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients are severely immunocompromised and susceptible to bacterial, viral, and fungal infections. Despite improved anti-microbial prophylaxis and preemptive strategies, bacterial bloodstream infections (BSIs) occur frequently in allo-HSCT recipients and are associated with increased morbidity and mortality. Cytomegalovirus (CMV) and Epstein Barr virus (EBV) are the most relevant viruses following allo-HSCT and remain major concerns. Fungal infections, including those caused by Candida and Aspergillus species, are persistent and feared complications.Areas covered: We aim to provide clinicians caring for allo-HSCT recipients with a comprehensive overview of the risk factors that predispose patients to common bacterial, fungal, and viral infections during the first years post-transplant. The focus is on the value of noninvasive diagnostic biomarkers and serological assays in enhancing the early detection and management of these infections.Expert opinion: Effective management of infectious complications following allo-HSCT relies on continuous immune recovery monitoring and the implementation of advanced diagnostic methods. Utilizing noninvasive diagnostic methods is crucial for early detection and different intervention strategies. The development and integration of reliable microbiological markers into clinical practice is essential for enhancing patient outcomes and mitigating infection-related risks. Emphasizing diagnostic innovation will be pivotal in advancing patient care post-allo-HSCT.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"291-303"},"PeriodicalIF":3.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142930912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of anti-PD1 immunotherapy and circulating tumor cells on progression-free survival in surgical pancreatic adenocarcinoma: a retrospective cohort study. 抗pd1免疫治疗和循环肿瘤细胞对手术胰腺腺癌无进展生存期的影响：一项回顾性队列研究

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-03-01 Epub Date: 2025-01-05 DOI: 10.1080/1744666X.2024.2448989

Yong-Gang He, Yi-Nan Zhu, Zhou-You Xiao, Zheng Wang, Chao-Qun Wang, Jing-Li, Xiao-Bing Huang, Lu Zheng

{"title":"Impact of anti-PD1 immunotherapy and circulating tumor cells on progression-free survival in surgical pancreatic adenocarcinoma: a retrospective cohort study.","authors":"Yong-Gang He, Yi-Nan Zhu, Zhou-You Xiao, Zheng Wang, Chao-Qun Wang, Jing-Li, Xiao-Bing Huang, Lu Zheng","doi":"10.1080/1744666X.2024.2448989","DOIUrl":"10.1080/1744666X.2024.2448989","url":null,"abstract":"Introduction: The clinical benefits of combining immunotherapy with chemotherapy and surgical resection in pancreatic adenocarcinoma remain unclear. The expression and clinical significance of HIF1A in circulating tumor cells (CTCs) in pancreatic adenocarcinoma remains limited.Methods: This retrospective cohort study compared survival outcomes in pancreatic adenocarcinoma patients treated with two regimens: surgery+chemotherapy (nab-paclitaxel plus gemcitabine)+anti-PD1 (Tislelizumab) (S+AG+anti-PD1) (n = 37), and surgery+chemotherapy (S+AG) (n = 5). The study also evaluated CTCs and HIF1A-positive CTCs as potential prognostic biomarkers.Results: The S+AG+anti-PD1 group (n = 37) showed significantly better progression-free survival (PFS) compared to S+AG (n = 15) in multivariate analysis (HR: 0.426, 95% CI: 0.185-0.983, p = 0.045). Overall survival (OS) differences were not statistically significant between groups. Lower CTC counts (≤1) were associated with longer PFS in surgical patients. This association was confirmed in multivariate analysis, after adjustment for AJCC stages (HR: 0.318, 95% CI: 0.104-0.974, p = 0.045). HIF1A-positive CTCs showed similar trends and prognostic significance to total CTC counts. Advanced AJCC stages remained the strongest independent predictor of worse PFS and OS.Conclusion: Combining surgery, chemotherapy, and immunotherapy may improve PFS in resectable pancreatic adenocarcinoma. While CTCs and HIF1A-positive CTCs may have prognostic value, AJCC staging remains the most reliable indicator.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"359-368"},"PeriodicalIF":3.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142914051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bullous pemphigoid and hypercoagulability: a review. 大疱性类天疱疮与高凝性：综述。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-03-01 Epub Date: 2025-01-08 DOI: 10.1080/1744666X.2025.2450766

Bingjie Zhang, Nan Yang, Li Li

{"title":"Bullous pemphigoid and hypercoagulability: a review.","authors":"Bingjie Zhang, Nan Yang, Li Li","doi":"10.1080/1744666X.2025.2450766","DOIUrl":"10.1080/1744666X.2025.2450766","url":null,"abstract":"Introduction: Bullous pemphigoid (BP) is an autoimmune blistering disease characterized by autoantibodies against hemidesmosomal proteins in the basal membrane zone. The presence of a high incidence of thrombotic events has led to the identification of a hypercoagulable state in BP patients.Areas covered: This review highlights the interactions between coagulation and immune-inflammatory responses based on the currently available literature, as well as individual changes in characteristic coagulation parameters in BP. This review is based on publications up to August 2024 that were retrieved by a selective search in the PubMed database.Expert opinion: The hypercoagulable state and bullous pemphigoid (BP) have a reciprocally enhancing effect on each other. For clinicians, it is crucial to closely monitor the fluctuations in circulating coagulation markers among BP patients, such as D-dimer, fibrinogen, and fibrin degradation products (FDP). Furthermore, considering the interplay between coagulation and immune-inflammatory responses in BP, targeting the shared pathways in treatment strategies could be beneficial for patients who exhibit both BP and a hypercoagulable state.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"323-332"},"PeriodicalIF":3.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142947120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Molecular investigations on T cell subsets in patients affected by hypomorphic DCLRE1C mutation. 受低形 DCLRE1C 基因突变影响的患者体内 T 细胞亚群的分子研究。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-03-01 Epub Date: 2024-05-09 DOI: 10.1080/1744666X.2024.2352479

Mehmet Ali Karaselek, Tugce Duran, Serkan Kuccukturk, Esra Hazar, Oznur Dogar, Ayca Kıykım, Sukru Guner, Ismail Reisli, Sevgi Keles

{"title":"Molecular investigations on T cell subsets in patients affected by hypomorphic DCLRE1C mutation.","authors":"Mehmet Ali Karaselek, Tugce Duran, Serkan Kuccukturk, Esra Hazar, Oznur Dogar, Ayca Kıykım, Sukru Guner, Ismail Reisli, Sevgi Keles","doi":"10.1080/1744666X.2024.2352479","DOIUrl":"10.1080/1744666X.2024.2352479","url":null,"abstract":"Objective: In this study, we explored the expression of transcription factors, cytokines, and co-stimulatory molecules within the helper T (Th) cell subsets (Th1, Th2, Th17, and Treg) of patients with hypomorphic DCLRE1C gene mutations.Methods: The study comprised eight patients and five controls. Transcription factor and cytokine expressions of Th subsets and co-stimulatory molecules were investigated by qPCR and flow cytometric following T cell stimulation. The findings were compared between patients (non-HSCT) and with hematopoietic stem cell transplantation (HSCT).Results: Flow cytometric analyses; while the Treg rate was significantly lower in non-HSCT than in controls (p = 0.010), the IFN-γ rate was significantly higher in patients than in the control and HSCT groups (p = 0.016, p = 0.022, respectively). Co-stimulatory molecule expressions were significantly lower in non-HSCT than in control (p < 0.001), and there was a significant improvement after HSCT. Post-stimulation qPCR analysis, significant changes were detected in non-HSCT/control, non-HSCT/HSCT, and HSCT/control comparisons.Conclusions: Our study is the first study to molecularly investigate Th cell subsets in hypomorphic DCLRE1C patients. It was determined that abnormalities in Th cell subsets still persisted despite HSCT. There are still many conditions to be explained in these patients, and we believe that our study may shed light on future studies.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"393-399"},"PeriodicalIF":3.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140853091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Serum adipocytokines and inflammatory cytokines in pregnant women with gestational diabetes mellitus: clinical utility and development of a risk prediction model. 妊娠期糖尿病孕妇血清脂肪细胞因子和炎症细胞因子：临床应用及风险预测模型的建立

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-03-01 Epub Date: 2024-12-13 DOI: 10.1080/1744666X.2024.2438714

Kezhuo Liu, Huihui Wang

{"title":"Serum adipocytokines and inflammatory cytokines in pregnant women with gestational diabetes mellitus: clinical utility and development of a risk prediction model.","authors":"Kezhuo Liu, Huihui Wang","doi":"10.1080/1744666X.2024.2438714","DOIUrl":"10.1080/1744666X.2024.2438714","url":null,"abstract":"Background: This study analyzed the clinical utility of serum adipocytokines and inflammatory cytokines in gestational diabetes mellitus (GDM) and developed a quantitative nomogram prediction model.Research design & methods: General data were collected. Fasting venous blood was taken and levels of fasting plasma glucose (FPG), serum adipocytokines, and inflammatory cytokines were assessed. The main risk factors for GDM were analyzed by implementing univariate and multivariate logistic regression analysis. The weights of the main risk factors were assigned, and the nomogram prediction model for GDM was developed by R software. The efficacy of the nomogram model for GDM prediction was measured and analyzed by the receiver operating characteristic (ROC) curve and calibration curve.Results: The observation group possessed a higher proportion of family history of diabetes, raised FPG, LEP, Visfatin, hs-CRP, IL-6, and TNF-α contents, and lower ADP contents (all p < 0.05). Multivariate logistic regression analysis displayed that LEP, ADP, and IL-6 were the main risk factors for GDM (p < 0.05). Calibration curve was basically consistent with the original curve, suggesting good accuracy.Conclusion: Serum adipocytokines and inflammatory cytokines were the main risk factors for GDM. Developing a nomogram model can facilitate early diagnosis of GDM by physicians, allowing for timely interventions.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"369-375"},"PeriodicalIF":3.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142779605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Future biomarkers for acute graft-versus-host disease: potential roles of nucleic acids, metabolites, and immune cell markers. 未来急性移植物抗宿主病的生物标志物：核酸、代谢物和免疫细胞标志物的潜在作用

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-03-01 Epub Date: 2024-12-18 DOI: 10.1080/1744666X.2024.2441246

Håkon Reikvam, Kimberley Hatfield, Miriam Sandnes, Øystein Bruserud

{"title":"Future biomarkers for acute graft-versus-host disease: potential roles of nucleic acids, metabolites, and immune cell markers.","authors":"Håkon Reikvam, Kimberley Hatfield, Miriam Sandnes, Øystein Bruserud","doi":"10.1080/1744666X.2024.2441246","DOIUrl":"10.1080/1744666X.2024.2441246","url":null,"abstract":"Introduction: Acute graft versus host disease (aGVHD) is a potentially lethal complication after allogeneic stem cell transplantation. Biomarkers are used to estimate the risk of aGVHD and evaluate response to treatment. The most widely used biomarkers are systemic levels of various protein mediators involved in immunoregulation or reflecting tissue damage. However, systemic levels of other molecular markers such as nucleic acids or metabolites, levels of immunocompetent cells or endothelial cell markers may also be useful biomarkers in aGVHD.Areas covered: This review is based on selected articles from the PubMed database. We review and discuss the scientific basis for further studies to evaluate nucleic acids, metabolites, circulating immunocompetent cell subsets or endothelial markers as biomarkers in aGVHD.Expert opinion: A wide range of interacting and communicating cells are involved in the complex pathogenesis of aGVHD. Both nucleic acids and metabolites function as soluble mediators involved in communication between various subsets of immunocompetent cells and between immunocompetent cells and other neighboring cells. Clinical and experimental studies suggest that both neutrophils, monocytes, and endothelial cells are involved in the early stages of aGVHD pathogenesis. In our opinion, the possible clinical use of these molecular and cellular biomarkers warrants further investigation.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"305-321"},"PeriodicalIF":3.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142817618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0